In a regulatory filing, Cytokinetics disclosed that on January 29, Ching Jaw, Senior Vice President & CFO, informed the company that he would be resigning his office and employment, effective February 23. Jaw’s stated reason for departure is to attend to a personal health condition and his departure is on mutually good terms between the company and himself.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
- Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
- Cytokinetics presents new data at CMR 2024 from FOREST-HCM
- Cytokinetics downgraded to Neutral from Buy at UBS
- Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024